STORM Therapeutics
Summary active Updated Apr 16, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
STORM Therapeutics is a Cambridge, UK-based clinical-stage biotechnology company targeting RNA modifications to reprogram cells and develop novel cancer therapies 1. The company’s lead program is STC-15, a first-in-class oral small-molecule inhibitor of METTL3, which has demonstrated durable tumor regression across multiple sarcoma subtypes in Phase 1 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-16 | Series C (insider round; no single lead named) | $56M | — (insider round) | M Ventures, Pfizer Ventures, Taiho Ventures, IP Group plc, UTokyo IPC, Fast Track Initiative — all returning existing investors 123 |
What Investors Say
No verified investor quotes available at this time.
What Founders Say
No verified founder quotes available at this time.
Sources
-
GlobeNewsWire, “STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC-15,” April 16, 2026. Accessed July 2026. https://www.globenewswire.com/news-release/2026/04/16/3275048/0/en/STORM-Therapeutics-Secures-56-Million-Series-C-Financing-and-Doses-First-Patient-in-Phase-2-Sarcoma-Trial-of-STC-15.html — Company press release confirms “The financing was funded by existing investors” (M Ventures, Pfizer Ventures, Taiho Ventures, IP Group, UTokyo IPC, Fast Track Initiative) with no single lead named. ↩↩↩
-
M Ventures news page, “STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC-15,” April 16, 2026. Accessed July 2026. https://www.m-ventures.com/news/storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-phase-2-sarcoma-trial-of-stc-15 — Investor’s own page independently confirming the round list and the “existing investors” characterization (no lead). ↩
-
Bioxconomy, “Storm Therapeutics strikes sarcomas with $56m Series C thunder,” April 2026. Accessed July 2026. https://www.bioxconomy.com/investment/storm-therapeutics-strikes-sarcomas-with-56m-series-c-thunder — Contemporaneous industry press confirming “The Series C funding round was backed entirely by existing investors” and no lead identified. ↩